Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Big Pharma Split's Total Liabilities for the quarter that ended in Jun. 2026 was C$14.04 Mil. Big Pharma Split's Total Assets for the quarter that ended in Jun. 2026 was C$33.47 Mil.
Therefore, Big Pharma Split's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.42.
Big Pharma Split (TSX:PRM) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Big Pharma Split Liabilities-to-Assets Related Terms
Big Pharma Split Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Big Pharma Split's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:PRM vs BLK, BX, KKR: Liabilities-to-Assets Comparison
For the Asset Management subindustry, Big Pharma Split's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Big Pharma Split Liabilities-to-Assets vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Big Pharma Split's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Big Pharma Split's Liabilities-to-Assets falls into.
Big Pharma Split Liabilities-to-Assets Calculation
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Big Pharma Split's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Big Pharma Split (TSX:PRM) has a Liabilities-to-Assets of 0.42 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Big Pharma Split and its competitors.
Is Big Pharma Split's Liabilities-to-Assets too high?
Big Pharma Split's current Liabilities-to-Assets is 0.42. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's Liabilities-to-Assets compare to BLK and BX?
Big Pharma Split's Liabilities-to-Assets of 0.42 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for an Asset Management company?
A good Liabilities-to-Assets depends on the Asset Management industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Big Pharma Split and its competitors. Big Pharma Split's current Liabilities-to-Assets is 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current Liabilities-to-Assets of 0.42. The stock's GF Value™ is C$1.80, compared to a current price of C$14.44 — trading 702.2% above its estimated fair value. The current Liabilities-to-Assets is 0.42. Big Pharma Split's overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current Liabilities-to-Assets is 0.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Big Pharma Split (TSX:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued.
The current stock price of C$14.44 is trading 702.2% above its estimated GF Value™ of C$1.80.
Key valuation signals for TSX:PRM:
Liabilities-to-Assets: 0.42
GF Value™: C$1.80 vs. price of C$14.44 (702.2% above fair value)
No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Big Pharma Split Corp is a Canadian closed-end investment fund corporation listed on the Toronto Stock Exchange. It invests in a portfolio of equity securities of large pharmaceutical companies, primarily those with operations in the United States, France, and the United Kingdom. The fund offers two classes of shares: preferred shares, which receive fixed cumulative preferential quarterly cash distributions, and class A shares, which receive regular monthly cash distributions plus the opportunity for capital appreciation. The fund employs a split-share structure, using the proceeds from preferred share issuance to fund the portfolio while directing dividend income and capital gains to class A shareholders. Its investment strategy focuses on established global pharmaceutical firms with stable dividend-paying histories, and it is managed by Harvest Portfolios Group.
7GF Score
Get the complete analysis for TSX:PRM
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRM has been successfully added to your 
